Show simple item record

dc.contributor.authorCesne, AL
dc.contributor.authorBauer, S
dc.contributor.authorDemetri, GD
dc.contributor.authorHan, G
dc.contributor.authorDezzani, L
dc.contributor.authorAhmad, Q
dc.contributor.authorBlay, J-Y
dc.contributor.authorJudson, I
dc.contributor.authorSchöffski, P
dc.contributor.authorAglietta, M
dc.contributor.authorHohenberger, P
dc.contributor.authorGelderblom, H
dc.date.accessioned2019-09-04T10:27:00Z
dc.date.issued2019-08-13
dc.identifier.citationBMC cancer, 2019, 19 (1), pp. 794 - ?
dc.identifier.issn1471-2407
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3330
dc.identifier.eissn1471-2407en_US
dc.identifier.doi10.1186/s12885-019-5988-3en_US
dc.description.abstractBackground PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between patient characteristics, prior lines of therapy, dose intensity, and dose modifications on safety and efficacy of pazopanib in aSTS.Methods PALETTE compared pazopanib with placebo in patients with aSTS (age ≥ 18 years) whose disease had progressed during or following prior chemotherapy. In these subgroup analyses, median progression-free survival (mPFS) among patients receiving pazopanib was the efficacy outcome of interest. Adverse events (AEs) were also compared within subgroups. All analyses were descriptive and exploratory.Results A total of 246 patients received pazopanib in the PALETTE study. The mPFS was longer in patients who had only 1 prior line versus 2+ prior lines of therapy (24.7 vs 18.9 weeks, respectively); AE rates were similar regardless of number of prior lines of therapy. The mPFS was similar in patients aged < 65 and ≥ 65 y (20.0 and 20.1 weeks, respectively). Although AEs leading to study discontinuation were higher in older patients (≥65 y, 30%; < 65 y, 17%), rates of dose reductions, dose interruptions, and serious AEs were similar between the 2 age groups. No reduction in mPFS was noted in patients requiring dose reductions or dose interruptions to manage toxicities.Conclusions Longer mPFS was observed in patients receiving pazopanib following only 1 line of therapy. Additionally, mPFS with pazopanib was maintained regardless of patient age or dose modifications used to manage toxicity.Trial registration NCT00753688 , first posted September 16, 2008 (registered prospectively).
dc.formatElectronic
dc.format.extent794 - ?
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectSarcoma
dc.subjectNeoplasm Metastasis
dc.subjectSulfonamides
dc.subjectPyrimidines
dc.subjectAngiogenesis Inhibitors
dc.subjectAntineoplastic Agents
dc.subjectNeoplasm Staging
dc.subjectTreatment Outcome
dc.subjectSurvival Analysis
dc.subjectRetrospective Studies
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectRandomized Controlled Trials as Topic
dc.subjectClinical Trials, Phase III as Topic
dc.titleSafety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
dc.typeJournal Article
dcterms.dateAccepted2019-07-29
rioxxterms.versionofrecord10.1186/s12885-019-5988-3
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-08-13en_US
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBMC cancer
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.publication-statusPublished
pubs.volume19en_US
pubs.embargo.termsNo embargo
icr.researchteamSarcoma Clinical Trialsen_US
dc.contributor.icrauthorJudson, Ianen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record